Actively Recruiting
Safety and Pharmacokinetic Study of ORX489 Tablets in Healthy Adults Aged 18 to 60 Years
Led by Centessa Pharmaceuticals (UK) Limited · Updated on 2026-02-25
212
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and how the body processes ORX489 in healthy adult volunteers aged 18 to 60 years. This Phase 1 study aims to learn about ORX489 after single and multiple doses, including its effects under different conditions such as normal and sleep-deprived states. Participants will be randomly assigned in a double-blind manner to receive ORX489 or placebo tablets in several study parts single ascending dose SAD in healthy adults, food-effect evaluation, multiple ascending dose MAD, and SAD in acutely sleep-deprived adults. Each part involves dosing followed by assessments up to 7 days after treatment. During the study, participants will undergo evaluations including blood tests to measure drug levels over time, sleepiness assessments like the Maintenance of Wakefulness Test and the Karolinska Sleepiness Scale, and safety monitoring throughout. Follow-up visits occur 7 days post-discharge to track any lasting effects, with total participation duration varying by study part.
CONDITIONS
Brief Title
A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years
Research Team
O
ORX489 Centessa Program Lead ORX489 Centessa Program Lead
C
Celerion Program Lead CA49982 United States, Nebraska [Recruiting]
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here